cognitieve stoornis cognitive decline impaired brain functioning
Conditions
Interventions
Subjects will receive a daily dose of 3.5g rumenic acid divided over six
capsules (intervention) or six placebo capsules (control).
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged 65 years or older - At risk of cognitive impairment/ memory complaints - Able to understand and perform the study procedures
Exclusion criteria
Exclusion criteria: - Body Mass Index (BMI) >35 kg/m2 - Current use of medication belonging to the *sartans* or *glitazones* - Current use of >500 mg/day of acetylsalicylic acid - Current use of medication that affects inflammation (anti-inflammatory medication) - Fish consumption of more than 1 serving per week - Current or recent (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study parameter is the performance on episodic memory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary parameters entail working memory, attention, executive functioning, and psychomotor speed as measured with a battery of cognitive tests, the evaluation of rumenic acid supplementation on anxiety, depressive symptoms, quality of life (measured with questionnaires), and fatty acid status (measured in blood). | — |
Countries
Netherlands
Outcome results
None listed